EV/EBITDA

Bio-Rad’s current EV/EBITDA of 17.2x means that for every dollar of its earnings before interest, taxes, depreciation, and amortization (EBITDA), investors are paying $17.20 for the entire enterprise value (market cap plus debt minus cash).

At 17.2x, the company trades well above the healthcare sector median of 13.3x and ranks in the 64th percentile among its sector peers, indicating it is more expensive than most similar companies. Over the last eight quarters the metric has been decreasing, though the quarter-over-quarter change is +4.1% (from 16.6x to 17.2x); no year-over-year data is available for comparison. The combination of a still-elevated valuation relative to peers and a declining long-term trend (recently reversed by a small uptick) suggests a mixed risk profile—the stock is not cheap, but the past downward movement may have reduced some previous premium. This metric generally supports the overall NEUTRAL verdict because the above-median level reinforces caution, while the directional uncertainty from the latest quarterly rise tempers any strong bullish or bearish tilt.

Frequently Asked Questions

Closest Sector Peers